Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.

ABSTRACT:

Objective

To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment.

Methods

A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle-Ottawa scale were used to assess the quality of included studies. Meta-analysis was performed using RevMan 5.3.

Results

Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non-antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR-PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78-1.14) and Day 14 (RR: 1.10; 95% CI: 0.96-1.25), and PCR negative conversion time (PCR-NCT; mean

SUBMITTER: Amani B 

PROVIDER: S-EPMC8426686 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature